﻿<?xml version="1.0" encoding="utf-8"?><?xml-stylesheet title="XSL_formatting" type="text/xsl" href="cms1260795.aspx"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><language>en-gb</language><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><lastBuildDate>Tue, 13 May 2008 04:23:45 GMT</lastBuildDate><title><![CDATA[aidsmap.com news feed : aidsmap news]]></title><description><![CDATA[aidsmap.com news feed : aidsmap news]]></description><copyright>Copyright NAM 2008</copyright><link>http://www.aidsmap.com</link><atom:link href="http://www.aidsmap.com/cms1260794.aspx" rel="self" type="application/rss+xml" /><image><title><![CDATA[aidsmap.com news feed : aidsmap news]]></title><url>http://www.aidsmap.com/files/file1002517.gif</url><link>http://www.aidsmap.com</link><width>122</width><height>44</height></image><ttl>15</ttl><item><title><![CDATA[Death rate in Malawi falls by up to 35% due to free HIV treatment]]></title><link>http://www.aidsmap.com/en/news/30FD449B-55C0-43DB-BB66-BC20D1F65D22.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">30FD449B-55C0-43DB-BB66-BC20D1F65D22</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[The death rate among adults in rural Malawi has declined by 10% since the introduction of antiretroviral therapy, and in areas with the highest death rate, it may have declined by up to 35%, according to findings from a London School of Hygiene and Tropical Medicine study published in the May 10th edition of The Lancet.
]]></description><category>Africa news</category><category>Statistics and epidemiology news</category><category>Treatment access news</category></item><item><title><![CDATA[HIV, but not HHV-8, found to increase risk of pulmonary arterial hypertension ]]></title><link>http://www.aidsmap.com/en/news/6C4D233B-52FF-4B27-A06B-0970638D81CF.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">6C4D233B-52FF-4B27-A06B-0970638D81CF</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[Higher pulmonary artery systolic pressure levels – an independent risk factor for pulmonary arterial hypertension – have been found in an HIV-positive study group, as compared to HIV-negative controls. However, no association with human herpesvirus-8 (HHV-8) infection was found. The results were reported in the April 23rd issue of AIDS.
]]></description><category></category></item><item><title><![CDATA[Circumcision and partner reduction should be priorities for HIV prevention, say US researchers]]></title><link>http://www.aidsmap.com/en/news/C823B941-D049-4978-AE79-D9A27EE36E8A.asp</link><author>Michael Carter</author><guid isPermaLink="false">C823B941-D049-4978-AE79-D9A27EE36E8A</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[Investigators in the US are calling for male circumcision and partner reduction to become the focus of prevention efforts in countries with generalised HIV epidemics. In a paper published in the May 9th edition of Science, they argue that although condom use, testing, and treatment of sexually transmitted infections are of value, resource constraints mean that attention should be shifted to the promotion of initiatives known to work: male circumcision and partner reduction.
]]></description><category>Africa news</category><category>Prevention news</category></item><item><title><![CDATA[Does tenofovir increase the risk of efavirenz-associated liver side-effects?]]></title><link>http://www.aidsmap.com/en/news/F459EAFC-6F8F-4AF3-B16D-28CFE436E57A.asp</link><author>Michael Carter</author><guid isPermaLink="false">F459EAFC-6F8F-4AF3-B16D-28CFE436E57A</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[Italian investigators have reported three cases which suggest that treatment with tenofovir (Viread) may increase the risk of liver side-effects caused by efavirenz (Sustiva). The reports are published in the May 11th edition of AIDS. 
]]></description><category>Changing treatments news</category><category>Palliative care news</category><category>Hepatitis news</category><category>Side-effects news</category></item><item><title><![CDATA[Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows]]></title><link>http://www.aidsmap.com/en/news/7CDD9DFC-54FD-49C6-9BB6-AD3313B0C9DB.asp</link><author>Michael Carter</author><guid isPermaLink="false">7CDD9DFC-54FD-49C6-9BB6-AD3313B0C9DB</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[The majority of patients with resistance to existing NNRTIs will benefit from treatment with etravirine (Intelence), a new, powerful NNRTI with a high barrier to resistance, according to a UK study published in the May 11th edition of AIDS. The investigators believe that the “next generation of NNRTIs, including etravirine, will play an important future role in sequencing HIV-infected patients who have acquired NNRTI resistant virus.”
]]></description><category>New drugs news</category><category>Resistance news</category></item><item><title><![CDATA[HIV reduces body's ability to control hepatitis C replication]]></title><link>http://www.aidsmap.com/en/news/58257C7C-AB10-418A-8F74-BADFBE0D78EA.asp</link><author>Adam Legge</author><guid isPermaLink="false">58257C7C-AB10-418A-8F74-BADFBE0D78EA</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[HIV infection significantly impairs the body’s ability to keep the replication of the hepatitis C virus (HCV) under control when coinfection occurs, says an international group of researchers in an article published in the June 1st edition of the Journal of Infectious Diseases (now online).
]]></description><category>Hepatitis news</category></item><item><title><![CDATA[BHIVA: Many patients and clinicians still need educating about the benefits of treatment]]></title><link>http://www.aidsmap.com/en/news/3E98C8D7-0FBD-4B1B-8F39-A55AE3FA12B6.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">3E98C8D7-0FBD-4B1B-8F39-A55AE3FA12B6</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[Both HIV-positive individuals and their clinicians require further education around the benefits of earlier initiation of therapy, and better understanding of the risks of treatment interruption, according to a Health Protection Agency (HPA) study presented to the 14th Annual British HIV Association (BHIVA) Conference last month in Belfast. 
]]></description><category>Conference news</category><category>UK news</category><category>Starting treatment news</category><category>Adherence news</category><category>Treatment access news</category><category>Palliative care news</category><category>Treatment interruptions news</category></item><item><title><![CDATA[Insulin resistance may predict risk of cardiovascular disease in HIV]]></title><link>http://www.aidsmap.com/en/news/A628C336-7EBE-4008-A3C3-E0F34D6D83AE.asp</link><author>David McLay</author><guid isPermaLink="false">A628C336-7EBE-4008-A3C3-E0F34D6D83AE</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[Insulin resistance may be a strong predictor of cardiovascular disease risk among people with HIV, says a report published in the April 23rd edition of AIDS. According to the study authors, determining the presence of insulin resistance in addition to calculating traditional risk scores may provide a fuller picture of cardiovascular disease risk in this population. 
]]></description><category>Lipodystrophy news</category><category>Side-effects news</category></item><item><title><![CDATA[Planned interruption of highly active antiretroviral therapy does not select drug resistance mutations in HIV-1-infected children]]></title><link>http://www.aidsmap.com/en/news/2B2FBFEF-FDE4-47AB-804F-0F84B6D2A956.asp</link><author>Tom Egwang</author><guid isPermaLink="false">2B2FBFEF-FDE4-47AB-804F-0F84B6D2A956</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[Stopping highly active antiretroviral therapy (HAART) containing two non-nucleoside reverse transcriptase inhibitors (NNRTI) for 9 or 14 days in HIV-1-infected children with viral suppression did not increase the risk of drug resistance, according to the results of a prospective multicentre study published in the May 15th edition of Clinical Infectious Diseases. 
]]></description><category>Resistance news</category><category>Treatment interruptions news</category><category>Children and HIV news</category></item><item><title><![CDATA[African-Americans with HIV have higher risk of aggressive kidney disease]]></title><link>http://www.aidsmap.com/en/news/03175361-06B3-4B6C-9394-D7FA26EE2D90.asp</link><author>Adam Legge</author><guid isPermaLink="false">03175361-06B3-4B6C-9394-D7FA26EE2D90</guid><pubDate>Tue, 13 May 2008 04:23:45 GMT</pubDate><image /><description><![CDATA[HIV-infected African-Americans who develop kidney disease are more likely to have a more aggressive form of the disease than white people with HIV, say US researchers writing in the June 1st edition of the Journal of Infectious Diseases.
]]></description><category>Palliative care news</category><category>Side-effects news</category></item></channel></rss>